Diagnostic Specialty Antibodies Market Growth Outlook Through 2024-2033

Spread the love

Overview and Scope

Diagnostic specialty antibodies refer to a class of antibodies that are specifically designed and developed for diagnostic purposes. These antibodies are utilized in various diagnostic tests and assays to detect and identify specific biomarkers, antigens, or pathogens in patient samples.

Sizing and Forecast

The diagnostic specialty antibodies market size has grown strongly in recent years. It will grow from $28.33 billion in 2023 to $29.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advancements in biotechnology, emergence of personalized medicine, increased disease understanding, immunoassay and diagnostic techniques, rise of companion diagnostics.

The diagnostic specialty antibodies market size is expected to see strong growth in the next few years. It will grow to $37.75 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to expanding disease biomarkers, rapid point-of-care testing, emerging infectious diseases, biosimilar and generic development, ai and machine learning integration. Major trends in the forecast period include technological advancements in assay development, integration of nanotechnology, enhanced specificity and selectivity, integration with wearable devices, continuous assay miniaturization.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report

Segmentation & Regional Insights

The diagnostic specialty antibodies market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies
2) By Application: Hepatitis, Tuberculosis, Dengue, Oncology, Human Immunodeficiency Virus (HIV), Infectious Disease, Other Applications
3) By End User: Diagnostic Laboratories, Hospitals

North America was the largest region in the diagnostic specialty antibodies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the diagnostic specialty antibodies market report during the forecast period. The regions covered in the diagnostic specialty antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12241&type=smp

Major Driver Impacting Market Growth

The growing patient pool for HIV diagnosis is expected to propel the growth of the diagnostic specialty antibodies market going forward. The growing patient pool of HIV diagnoses refers to an increasing number of individuals who are being diagnosed with HIV (Human Immunodeficiency Virus). As the number of individuals being diagnosed with HIV increases, the market for diagnostic specialty antibodies expands, creating opportunities for manufacturers to develop and supply specialized antibody-based diagnostic products for HIV testing, enabling the detection of specific biomarkers associated with the virus and aiding in the early detection and monitoring of HIV infection. For instance, in July 2022, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based UN program dedicated to addressing the global HIV or AIDS epidemic, the global population living with HIV increased by 1.6% from 37.8 million in 2020 to 38.4 million in 2021. Further, there were approximately 1.5 million new HIV infections reported in 2021. Therefore, the growing patient pool of HIV diagnoses is driving the growth of the diagnostic specialty antibodies market.

Key Industry Players

Major companies operating in the diagnostic specialty antibodies market report are F. Hoffmann-La Roche AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Boehringer Ingelheim International GmbH, Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc, Agilent Technologies Inc., Sartorius AG, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., STEMCELL Technologies Inc., Abcam PLC, Telix Pharmaceuticals Limited, Aytu BioScience Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics, Novus Biologicals LLC, Confo Therapeutics SA, Precirix NV, Creative Biolabs Inc., Polymun Scientific ImmunbiologischeForschung GmbH.

The diagnostic specialty antibodies market report table of contents includes:

1. Executive Summary

2. Diagnostic Specialty Antibodies Market Characteristics

3. Diagnostic Specialty Antibodies Market Trends And Strategies

4. Diagnostic Specialty Antibodies Market – Macro Economic Scenario

 

5. Global Diagnostic Specialty Antibodies Market Size and Growth

32. Global Diagnostic Specialty Antibodies Market Competitive Benchmarking

33. Global Diagnostic Specialty Antibodies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Diagnostic Specialty Antibodies Market

35. Diagnostic Specialty Antibodies Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →